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Depression is one of the most prevalent health problems, frequently being a medium- and
long-term condition, with a high comorbidity rate and with frequent relapses and recur-
rences. Although numerous studies have compared the effectiveness of specific antidepres-
sant therapy drugs and have assessed relapses, scientific evidence on the relationship
between pharmacologic treatments and recurrence is scarce. The objective of this study is
to describe depressive episodes in a primary care patient cohort, the percentage of depres-
sion recurrences and the administered pharmacologic treatment, from a naturalistic
perspective.
Methods
Retrospective descriptive study. 957 subjects were included. The dependent variable was a
depression diagnosis and independent variables were: gender, age at time of data collec-
tion; age of onset, first-episode treatment, number of recurrences, age at recurrences, treat-
ment prescribed for recurrences using therapeutic groups categorization.
Results
Recurrences are frequent, affecting more than 40% of the population. In the first episode,
13.69% of the patients were not prescribed pharmacological treatment, but this percentage
decreased over the following depression episodes. 80.9% of the patients who did not
receive drug treatment in the first depression episode did not experience subsequent epi-
sodes. Monotherapy, and specifically, SSRIs were the most frequently prescribed treatment
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option for all depressive episodes. Regards the combined pharmacologic treatment, the
most frequent drug combinations were SSRIs and benzodiazepines.
Limitations
In order to increase the power of results, the statistical analysis was performed using thera-
peutic groups categorization, not individually analyzing each drug and dose.
Conclusions
Depressive episode recurrence is frequent in primary care patients. Further studies having
a prospective design are needed in order to expand on this issue.
Introduction
Depression is one of the most prevalent health problems in primary care, [1–3] and is one of
the four medical conditions causing the largest number of disabilities [1,4,5]. Women typically
have a two-fold increased risk of major depression as compared to men [6], and the peak age
of risk for the first onset of a major depressive episode (including bipolar depression) is esti-
mated to range from mid-late adolescence to the early 40s [7]. It is also the most expensive
mental disorder, accounting for 1% of the Gross Domestic Product (GDP) of the European
Union [8–10]. This mental health problem is often a medium- and long-term condition, hav-
ing a high comorbidity rate [11,12].
Major depressive disorder (MDD) is highly recurrent [2,3,13], making the prevention of
depressive relapse and recurrence depression one of the most important challenges to its man-
agement [14]. The ‘MacArthur Research Network on the Psychobiology of Depression’ pro-
posed operational criteria for the constructs of response, remission, recovery, relapse and
recurrence [3,15,16] as guidance for the field. According to these criteria, remission occurs
when symptoms have largely normalized and the patient can be considered well for a given
period of time (often defined as two months or longer), and precedes both recovery and recur-
rence. Relapse suggests the reemergence of depression symptoms (presumably part of the
depressive episode) following some degree of remission but preceding recovery; and recur-
rence implies the onset of a new depression episode following an extended period of remission,
sufficiently long so as to assume that recovery had taken place.
Recurrences occur frequently [17,18]. Individuals suffering from an initial depressive epi-
sode have a 40% to 60% chance of experiencing a subsequent episode; individuals with 2 epi-
sodes have approximately 60% to 70% possibility; and for individuals experiencing three
episodes, the risk is up to 90% [3,17,19,20]. The mean time of the recurrence following the ini-
tial episode is approximately three years, and subsequent episodes usually appear after 1 or 1.5
years. Recurrence risk is higher during the initial months following recovery [19]. Subse-
quently, mean time of recurrence progressively decreases, and length of recovery increases; in
a study [21] performed on a Dutch population, patients suffering from major depression who
recovered presented a cumulative recurrence range of 13% in 5 years, 23% in 10 years and 42%
in 20 years, respectively.
Previous bibliographies have highlighted certain factors involved in the recurrence of
depression, such as the severity of major depression episodes (MDE) [22,23]; the number of
depressive episodes experienced [22–24], early age of onset of first MDE [22], comorbidity
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with axis I and axis II psychiatric pathology [22]; change in the size of specific brain areas [25];
immunologic irregularities [26]; history of suicide attempts [22]; family history of depression
[27]; concurrent physical health problems and psychosocial difficulties [28]; stressful live
events [29], and female gender and older age [22].
As for drug therapy, interruption of antidepressant treatment when in remission from the
depressive episode leads to a risk of recurrence in 40–50% of the patients, whereas maintaining
the treatment for 6 to 12 months after remission reduces this risk to 13–20% [30–32].
Although many studies have compared the effectiveness of specific antidepressant therapy
drugs and have assessed relapses, there is little scientific evidence regarding the relationship
between pharmacologic treatments and recurrence. To our knowledge, no studies have ana-
lyzed the relationship between antidepressant pharmacologic strategies and depression recur-
rence. Only a few meta-analyses include studies of specific drugs versus placebo, obtaining
inconclusive conclusions [33–35]. Therefore, there is insufficient knowledge on the association
between the different classes and combinations of psychoactive drugs and the occurrence of
such relapses and recurrences.
Primary health care services are the ideal setting for carrying out recurrence prevention
strategies. More than 80% of all patients suffering from depression are currently managed by
primary health care and drug therapy is the first-line treatment. So, antidepressant consump-
tion has increased over recent years in Europe [36,37]. Antidepressant use has been reported
to be higher in women and it tends to increase with age [38], with selective serotonin reuptake
inhibitors (SSRIs) being the top choice, according to clinical practice guidelines [39].
Therefore, the aim of this study is to describe depressive episodes in a primary care patient
cohort, the percentage of depression recurrences and the administered pharmacologic treat-
ment, from a naturalistic perspective. This article provides comprehensive insights into antide-




Retrospective observational cohort study.
Study population and sample size
Data were obtained from the clinical histories of patients over the age of 18 at a primary care
center in Zaragoza (Spain) between October 2017 and February 2018. This health care center
attends to 18,875 patients. From this population, patients were selected based on the following
inclusion criteria: 1) Aged 18 and over; 2) having been diagnosed with major depression (codi-
fied as depressive disorder according to the World Organization of Family Doctors (WONCA)
ICPC-2) diagnosed by his/her primary care physician between 2001 and 2017. Exclusion crite-
ria were: 1) Database inconsistencies; 2) having a clinical history of less than two years at the
time of the study; 3) having a severe psychiatric disorder comorbidity (schizophrenia or bipo-
lar disorder); 4) presenting dysthymia and 5) patients referred to and followed up on by the
psychiatric unit.
The population cared for in this health center is aged, having an aging rate of 224.65%, an
over-aging rate of 17.53%, and with 22.05% being immigrants. The percentage of males is
47.60%, having a mean age of 45 years and 10 months, whereas women account for 52.40%,
with a mean age of 48 years and 10 months. The percentage of the population aged 25 and
younger is 21.25% and those over the age of 60 account for 27.2% [40].
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The sample size included 957 subjects meeting the selection criteria. Fig 1 shows the flow-
chart of the sample size.
Study variables and data collection
Data were collected retrospectively from the computerized clinical histories of all primary care
patients assigned to the selected health care center. The dependent variable was the depression
diagnosis (The P76 International Classification of Primary Care 2˚ edition (ICPC-2) code of
the World Organization of Family Doctors (WONCA) was used). The definition of recurrence
created by Frank et al. and followed in various studies [3,14,16,17] has been used. Therefore,
recurrence is considered to be a diagnosis made by the family physician, for a new depression
episode (after having suffered an initial episode) in the case in which there was a previous
remission of a sufficient duration so as to assume that recovery had occurred. A minimum
period of 6 months following the end of treatment, according to the computer-based clinical
history, was considered for the definition of a recurrence episode. Since this is a retrospective
study, no validation has been conducted for the diagnosis made by the family physician.
Fig 1. Flowchart of the sample.
https://doi.org/10.1371/journal.pone.0233454.g001
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Independent variables were gender, age at time of data collection, age of onset, first-episode
treatment prescription and Anatomical Therapeutic Chemical (ATC) drug code, recurrence
and number of recurrences, age at recurrences, treatment prescribed for recurrences and drug
ATC code, and time to recurrences. Pharmacologic treatment has been grouped according to
therapeutic group (ATC classification) [41] and is shown in Table 1. Benzodiazepines were
collected, despite not being antidepressants, since they are frequently prescribed for this psy-
chopathology. Using the patient’s clinical history, it is possible to determine if the prescription
is collected from the community pharmacies, so the family physician can assess the therapeutic
adherence and intervene when considered necessary. In cases in which the family physician
did not prescribe any pharmacological treatment, based on his/her clinical criteria, this has
also been noted.
These variables were collected retrospectively from 2018 to 2001. The cut-off point was
2001, since this was the year as of which the computer-based clinical history was available and
fully established at this health center. Given the universal nature of the health system and the
absence of other primary health care providers, the data obtained in the study is considered to
be representative of almost 100% of the population that met the study’s inclusion criteria.
Statistical analysis
A descriptive analysis of the sample was conducted using means and standard deviations for
continuous data and frequencies and percentages for categorical data. The following non-
parametric tests (Shapiro-Wilk test p-value< 0.001) were used to analyze the relationship
Table 1. Pharmacologic treatment according to therapeutic group (ATC classification).
Therapeutic group Active ingredient
Benzodiazepines Alprazolam/Trankimazin, Bentazepam, Bromazepam, Clonazepam,
Clorazepate Dipotassium, Diazepam, Midazolam, Ketazolam,
Lorazepam, Lormetazepam, Medazepam, Piracetam, Tepazepam,
Halazepam/Flurazepam
Selective Serotonin Reuptake Inhibitors
(SSRIs)
Citalopram, Escitalopram, Fluoxetine, Paroxetine, Sertraline,
Fluvoxamine










Serotonin antagonist and reuptake
inhibitors (SARIs)
Trazodone
Noradrenergic and specific serotonergic
antidepressants (NaSSAs)
Mirtazapine
Melatonin receptor agonist (MRA) Agomelatine
Serotonin activity modulator (SMS) Vortioxetine
Hypnotics Zolpidem
Antiepileptic Topiramate
Typical Neuroleptics Levomepromazine, Haloperidol, Trifluoperazine
Atypical Neuroleptics Quetiapine, Risperidone, Olanzapine
Non-specific drugs Melitracen/flupentixol, Deanol/heptaminol, Vitamin B complex,
Piridoxine/Sulbutiamine, Levosulpiride/sulpiride, Gabapentin
https://doi.org/10.1371/journal.pone.0233454.t001
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between demographic variables and recurrence apparition (yes/no) and the number of recur-
rences: Mann–Whitney U and Kruskal Wallis for numerical variables, and Chi-square and
Fisher tests for categorical ones. Pharmacologic treatments were grouped into ATC categories
to provide a more robust analysis.
Ethical considerations
The authors declare that all procedures contributing to this work comply with the ethical
standards of the Declaration of Helsinki of 1975, as revised in 2008. The study protocol was
approved by the Clinical Research Ethics Committee of Aragón (Spain) (PI18/029) and by the
Aragón Health Service. The database of the pharmacological treatment was facilitated anony-
mously by the Aragon Healthcare Department. This study forms a part of another study whose
main objective is to analyze the risk factors for the recurrence of a major depression episode
included in the literature and specifying the weight of each of these in a sample of subjects that
have experienced a major depression episode during their life. Patients wishing to participate
were requested to sign an informed consent form for data collection via questionnaire.
Results
A total of 957 subjects were diagnosed with major depression during the study period. Of
these, 708 (73.98%) were women and 249 (26.02%) were men. Their mean age was 60.95 years
(SD: 17.33). As for the number of recurrences, more than half, 59.1% (566 patients) did not
have recurrence events, while 40.9% (391 patients) experienced a second depressive episode.
A third depression diagnosis took place in 14.8% (142 patients) and 3.8% (36 subjects) experi-
enced a fourth depression event. Therefore, of the patients having a second episode of depres-
sion, 36.31% experienced a third event, and of these, 25.32% had a fourth depression
diagnosis. The p-value (tendency) revealed an increase in age as the number of recurrences
increased (p(tendency)< 0.001). The mean time between the first and second episodes was
4.51 years (SD: 3.35), 3.75 years (SD: 2.23) between the second and third episodes, and 3.53
years (SD: 2.23) between the third and fourth episodes. Significant differences were found
between men and women, both in number of recurrences and percentage of subjects suffering
from depression recurrences. The number of recurrences and age of first episode are higher
for women. All of these differences are shown in Table 2.
Table 2. Differences between men and women in number of recurrences; mean age at diagnosis of depressive episodes and time to recurrences.
N (men / women) MEN% / Mean (SD) WOMEN% / Mean (SD) p-value
Number of recurrences 249/708 0.48 (0.73) 0,63 (0.85) 0.022
1st recurrence (%) 88/303 35.34% 42.79% 0.040
2nd recurrence (%) 28/114 11.24% 16.10% 0.064
3rd recurrence (%) 4/32 1.60% 4.51% 0.038
Age 1st at diagnosis 249/708 49.89 (17.62) 52.95 (17.10) 0.017
Age 2nd at diagnosis 88/303 55.78 (18.33) 58.42 (16.35) 0.280
Time between 1st and 2nd diagnosis 88/303 4.97 (3.78) 4.37 (3.21) 0.268
Age at 3rd diagnosis 28/114 62.64 (17.83) 61.61 (15.47) 0.667
Time between 2nd and 3rd diagnosis 28/114 3.57 (2.55) 3.79 (2.59) 0.589
Age at 4th diagnosis 4/32 59.25 (20.10) 63.97 (13.48) 0.752
Time between 3rd and 4th diagnosis 4/32 3.75 (3.20) 3.50 (2.15) 0.942
Statistic used: Mann–Whitney U (Chi square and Fisher test were used for the percentage of subjects suffering a first, second or third recurrence).
https://doi.org/10.1371/journal.pone.0233454.t002
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In the first episode, 13.69% of the patients were not prescribed pharmacological treatment,
based on the criteria of their family physician; 45.45% were prescribed drugs for depression
treatment in monotherapy, and 40.86% were prescribed polytherapy drug treatment. As for
the patients who were not prescribed drug treatment in the first depression episode, their per-
centage rose to 13.69%, but it decreased over the following depression episodes. 80.9% of the
patients who did not receive drug treatment in the first depression episode did not experience
subsequent episodes; 16% experienced one subsequent episode and 3.1% experienced two sub-
sequent episodes.
As for pharmacologic treatment, SSRIs and benzodiazepines, specifically paroxetine, escita-
lopram and lorazepam were the most frequently prescribed drugs for all depression episodes.
This latter drug was prescribed mainly in combination with other medications. Paroxetine was
prescribed to 27.48% of the patients in their first episode, to 26.11% in their second, to 25.92%
in their third and 26.66% in their fourth episode. Escitalopram was prescribed to 14.048% of
the patients in the first episode, to 18.61% in the second, to 26.67% in the third and to 26.66%
in the fourth episode.
As for anxiolytics, the second therapeutic group prescribed as a complementary antidepres-
sant treatment, lorazepam was prescribed to 26.27% of the patients in the first episode, to
21.66% in the second, to 21.48% in the third and to 23.33% in the fourth episode.
Monotherapy, and specifically, SSRIs were the most frequently prescribed treatment option
for all depressive episodes. In all depression episodes, patients were mainly treated with a
SSRI. Benzodiazepines and SNRIs were also prescribed slightly more often than the other ther-
apeutic groups. No prescriptions of NRI, MRA or typical neuroleptics were prescribed in
monotherapy.
As for combined pharmacologic treatment, in the first depression episode, a total of 50 dif-
ferent drug combinations were found: 29 combinations of drugs and 21 combinations of three
medicines. There were 13 drug combinations prescribed to 86.96% of the patients via polyther-
apy. In the other depression episodes, the number of combinations was lower. The most fre-
quent drug combinations were SSRIs and benzodiazepines. Tables 3–5 describe all types of
treatments, both in monotherapy and polytherapy, for each depression episode.
Discussion
The results of this retrospective cohort study reveal a percentage of the population in which
recurrence of depressive episodes occurs frequently. In our study, 40% of all patients suffered
at least one recurrence. The study by Solomon et al. [20] revealed higher numbers; 66% of the
subjects having an initial depression episode experienced at least one recurrence during 10
years of follow up. Other studies [16,19,42] however, have suggested a lower prevalence, with
recurrences taking place in approximately 33%, a figure which is more in line with our study.
As for the age in which the depression episodes were diagnosed, we have found high figures,
given that the mean age at first diagnosis for men is 49.89 (SD: 17.62) and 52.95 in women
Table 3. Description (frequency and percentage) of treatment types (non-pharmacologic, monotherapy and polytherapy) for each depressive episode.
Treatment 1st episode Frequency (%)
N = 957
2nd episode Frequency (%)
N = 391
3rd episode Frequency (%)
N = 142




131 (13.69%) 31 (7.92%) 7 (4.93%) 6 (16.66%)
Monotherapy 435 (45.45%) 206 (52.69%) 83 (58.45%) 19 (52.78%)
Polytherapy 391 (40.86%) 154 (39.39%) 52 (36.62%) 11 (30.56%)
https://doi.org/10.1371/journal.pone.0233454.t003
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Table 5. Description (frequency and percentage) of combined pharmacologic treatment (ATC classification) for each depressive episode.
Pharmacological polytherapy 1st episode Frequency (%)
N = 391
2nd episode Frequency (%)
N = 154
3rd episode Frequency (%)
N = 52
4th episode Frequency (%)
N = 11
Combination of 2 drugs
SSRI+ benzodiazepine 218 (55.76%) 79 (51.3%) 28 (53.85%) 8 (72.73%)
SSRI+ non-specific medicine 16 (4.10%)
SSRI+ NaSSA 6 (1.53%) 4 (2.60%) 4 (7.69%)
SSRI+ hypnotic 15 (3.83%)
TCA + Benzodiazepine 8 (2.05%)
SNRI + Benzodiazepine 32 (8.18%) 14 (9.09%) 4 (7.69%)
SNRI+NaSSA 5 (1.95%)
Heterocycle + Benzodiazepine 4 (1.02%)
Nonspecific medicine + Benzodiazepine 8 (2.05%)
NaSSA + Benzodiazepine 5 (1.28%)
SARI + Benzodiazepine 4 (2.60%)
Benzodiazepine + Benzodiazepine 7 (1.79%) 4 (2.60%)
Combination of 3 drugs
SSRI + 2 Benzodiazepine 12 (3.07%)
SSRI + non-specific medicines
+ Benzodiazepine
5 (1.28%)
SNRI + NaSSA + Benzodiazepine 4 (1.02%)
SSRI + hypnotic + Benzodiazepine 4 (2.60%)
Other combinations with a frequency< =
3 subjects
51 (13.04%) 16 (30.77%) 3 (27.27%)
SSRI, Selective Serotonin Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SNRI, Serotonin–norepinephrine reuptake inhibitors; SARI, Serotonin antagonist and
reuptake inhibitors; NaSSA, Noradrenergic and specific serotonergic antidepressants.
https://doi.org/10.1371/journal.pone.0233454.t005
Table 4. Description (frequency and percentage) of pharmacologic treatment (ATC category) in monotherapy for each depression episode.
Pharmacologic
treatment
1st episode Frequency (%)
N = 435
2nd episode Frequency (%)
N = 206
3rd episode Frequency (%)
N = 83
4th episode Frequency (%)
N = 19
Benzodiazepine 47 (10.76%) 18 (8.74%) 6 (7.23%) 2 (10.53%)
SSRI 290 (66.66%) 138 (66.99%) 55 (66.27%) 11 (57.89%)
TCA 9 (2.06%) 2 (0.97%) 1 (1.20%) 1 (5.26%)
SNRI 40 (9.15%) 21 (10.19%) 15 (18.07%) 2 (10.53%)
Heterocycle 5 (1.14%) 1 (0.49%)
NDRIs 3 (0.69%) 1 (0.49%)
SARI 2 (0.46%) 4 (1.94%) 4 (4.82%) 1 (5.26%)
NaSSA 13 (2.97%) 9 (4.37%) 1 (5.26%)
SMS 1 (0.23%) 1 (0.49%) 1 (5.26%)
Hypnotic 3 (0.69%) 5 (2.43%)
Anti-epileptic 1 (0.49%) 1 (1.20%)
Atypical neuroleptics 3 (0.69%) 1 (0.49%)
Non-specific medicines 19 (4.35%) 4 (1.94%) 1 (1.20%)
SSRI, Selective Serotonin Reuptake Inhibitors; TCA, Tricyclic Antidepressants; SNRI, Serotonin–norepinephrine reuptake inhibitors; NDRI, Noreprinephrine-
dopamine reuptake inhibitors; SARI, Serotonin antagonist and reuptake inhibitors; NaSSA, Noradrenergic and specific serotonergic antidepressants; SMS, Serotonin
activity modulator.
https://doi.org/10.1371/journal.pone.0233454.t004
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(SD: 17.10). In the study by Kessler and Bromet [6], the WHOWorld Mental Health (WMH)
survey revealed that the median retrospectively-reported age of onset of depression episodes
was the mid-20s, with the interquartile range indicating that across all countries, the peak risk
period for the onset of MDD ranged from mid-late adolescence to the early 40s. In a study by
Bockting et al [3], based on theWorld Mental Health Survey Initiative Version of the World
Health Organization Composite International Diagnostic Interview (WMH-CIDI), the
median age of onset (i.e., 50th percentile of the age-of-onset distribution) was the 30s for
mood disorders. However, of the high income countries, Spain has one of the latest median
ages of onset, at 30.0 years [6]. However, there may be other causes for this, including the fail-
ure of family physicians to diagnose younger patients, given the high population of immigrants
in the healthcare system who are older [40], or since there may have been prior episodes that
were not considered and that may have been omitted when transferring the clinical histories
to electronic means due to patient mobility between health centers. As for the failure to diag-
nose, under-diagnosis and a difficulty of diagnosis occur in primary healthcare centers [43,44],
since it is based on criteria and often not on very specific symptoms, which may be difficult to
recognize by poorly trained professionals [45,46]. Although the most common stage of onset
for mood disorders occurs during early adulthood (specifically, at the age of 30) [2], young
adults do not tend to seek out health assistance given the related social stigma [47] or, in the
case of young men from deprived backgrounds, they often fail to recognize a mental health
problem and are less likely to suggest visiting a doctor than women [48].
In our research, the mean time between the first and second episode was 4.51 years (SD:
3.35), and this period was lower as the number of recurrences increased. This tendency has
been seen previously in the bibliography, although the mean time of recurrence was lower,
approximately 3 years for the time between the first and second episode and 1 to 1.5 years for
subsequent episodes (Solomon et al., 2000). Additional research on the role of age as a sociode-
mographic factor is necessary, since in our study, a positive relationship was found between
the number of recurrences and age, while in a review of naturalistic cohort studies [16], no
association was found between this factor and the possibility of recurrence.
As for patients who are not prescribed drug treatment, this decision, made by the family
physician, to not prescribe anything, may be related to the severity of the depressive episode,
since disorder severity has been correlated with the probability of treatment [49]. In addition,
clinical practice guidelines [32,50] have established recommendations for gradual treatment,
based on scientific evidence; they recommend that the onset of intervention be the less intru-
sive of those that have been proven effective. In the computerized clinical history, the severity
of the depression episode is not included. Therefore, it has been impossible to analyze whether
these patients who did not receive pharmacological treatment were those having the mildest
symptomology. A high percentage of these patients, (over 80%), however, did not experience
recurrence.
According to current recommendations for antidepressants in patients suffering from uni-
polar depression [39], SSRIs and SNRI, more recently Duloxetine, Venlafaxine, and Desvenla-
faxine, are the first line of treatment. These antidepressants were the most frequently
consumed in our sample of patients, so we can assume that treatment for depression in pri-
mary care is consistent with clinical practice guideline recommendations.
Despite scientific evidence on the effectiveness and safety of these treatments, few studies
have analyzed the relationship between antidepressant treatment and the recurrence of depres-
sion. In a meta-analysis conducted to establish the effectiveness of antidepressant treatment in
preventing recurrence, 37 studies were analyzed, with 7,253 patients and comparing 24 differ-
ent antidepressants with placebo. In 35 of these studies, antidepressant treatment was more
effective than the placebo at preventing recurrence (RR = 2.03, CI 1.80–2.28, NNT = 3.8;
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p< 0.0001), but no significant differences were observed regarding the different treatments
analyzed [33]. Nevertheless, other research has found variations based on the administered
treatment. In a double-blind study analyzing time to recurrence appearance, fluoxetine was
found to produce a longer time to recurrence as compared to venlafaxine [51]. In another
study in which the effectiveness of treatment was analyzed, in terms of 24 months without
recurrences [52], it was found that bupropion and fluvoxamine were the least effective in
preventing recurrence of depression. In this study, and in line with our results, duloxetine was
more effective in this sense. The authors conclude that the balance between dopamine, seroto-
nin and noradrenaline may play a major role in the prevention of recurrences. Thus, an
increased dopaminergic activity may not be useful in this sense, as occurs with the use of
bupropion alone. However, a dual action, such as treatment with SNRI, could provide protec-
tion from recurrences.
Based on this theory, in our cohort of patients, SNRI and NaSSA were the only treatments
that were not related to recurrences. Both therapeutic groups present a different mechanism of
action, but they share a simultaneous and specific action over serotonin and noradrenaline.
Future studies should attempt to demonstrate this hypothesis.
With respect to the prescription of benzodiazepines, insomnia has been described as a
potential modifier of antidepressant treatment response [53] and anxiety disorder has been
found to have a direct negative effect on the overall course of the disease and the lack of
response to pharmacological treatment [54–56]. A randomized double-blind study revealed
that high levels of anxiety not only increase failure of acute treatments but also raise the risk of
recurrences over the two years following episode remission, despite being used as an optimal
antidepressant therapy [54]. This suggests that the preventive effect of SNRIs and NaSSAs can
be neutralized depending on the nature of the depressive episode.
This study has numerous strengths, but it also faces certain limitations. On the one hand, it
examines recurrences in a cohort of patients across a 16-year-period, not only from an epidemio-
logic point of view, but also based on pharmacologic treatment, providing a more comprehensive
view of this phenomenon. Its limitations mainly relate to the information source, since some rele-
vant data were not registered in the database, such as length of the treatment and duration of the
depressive episode, or the severity of the same, and were not considered in the research. Severity
of the depressive episode is not usually collected by primary care physician. The active ingredient
dosage, although collected, has not been considered in the statistical analysis, since inclusion of
this variable led to a loss of power in the results and caused confusion, especially with respect to
combined drug treatment. The supposition is that the severity of those patients who did not
receive drug treatment was milder, since this is the protocol recommended by clinical practice
guidelines [32,50]. However, this relationship cannot be established since this variable is not
included in the computerized clinical history. Further studies are needed to examine the relation-
ship between seriousness and the duration of the pharmacological treatment, since both variables
may shed light on the phenomenon of recurrence of depression [32].
Other aspects to be considered as study limitations include the diagnosis of depression
made by the family physician, since as previously mentioned, there is an under-diagnosis in
primary care [43,44]; and the existence of comorbidities. In this study, only serious psychiatric
comorbidities have been considered as exclusion criteria. As for comorbidity, a study by Gili
et al [12] that compared the comorbidity of affective disorders and medical diseases in primary
care patients with either a first or recurrent depressive episode, revealed that all medical condi-
tions were more prevalent in the recurrent patients group than in the first-episode group
(aOR = 2.61, CI = 2.31–2.93), after adjusting for gender, age, education, socioeconomic status
and body mass index. In this study, the suitability of drug treatment based on patient comor-
bidities has not been examined, given that the objective is to describe depressive episodes in a
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primary care patient cohort and the administered pharmacologic treatment, from a naturalis-
tic approach. Due to the universal nature of the healthcare system and the absence of other pri-
mary healthcare providers, it is known that subjects did not receive other pharmacological or
psychological treatment from the healthcare system, but it is not known if they may have
received some psychological therapy from outside of the national healthcare system. This may
be considered a potential study limitation, since cognitive behavioral interventions, which may
be carried out during the acute phase, appear to have a lasting protective effect on patients,
preventing relapse and perhaps, recurrence upon treatment termination [3]. Finally, the sam-
ple has consisted mainly of female patients, as expected in Mediterranean countries in which
women are almost three times more likely to suffer fromMDD than men [57]. This fact,
together with the aging population may further limit the generalization of our data. However,
no clear influence of gender on antidepressant response has been reported in literature, at least
for outpatients [58] and an aging population is a common demographic phenomenon in
many developed countries.
Conclusion
Recurrence of depressive episodes is frequent in primary care patients, affecting more than
40% of the population, being more common in women. Monotherapy and specifically SSRIs
were the most frequently prescribed treatment option for all depressive episodes. As for com-
bined pharmacologic treatment, the most frequently prescribed drug combinations were
SSRIs and benzodiazepines.
Acknowledgments
We wish to thank the Primary Care Prevention and Health Promotion Network (RedIAPP-
Health Institute Carlos III, Spain); Research Group B21_R17 of the Department of Science,
University and Knowledge Society of the Government of Aragon (Spain) and Feder Funds
"Another way to make Europe".
Author Contributions
Conceptualization: Shysset Nuggerud-Galeas, Rosa Magallón Botaya, Bárbara Oliván
Blázquez.
Data curation: Shysset Nuggerud-Galeas.
Formal analysis: Rosa Magallón Botaya, Bárbara Oliván Blázquez.
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7. BogrenM, Brådvik L, Holmstrand C, Nöbbelin L, Mattisson C. Gender differences in subtypes of
depression by first incidence and age of onset: a follow-up of the Lundby population. Eur Arch Psychia-
try Clin Neurosci [Internet]. 2018Mar 18 [cited 2019 Sep 18]; 268(2):179–89. Available from: http://
www.ncbi.nlm.nih.gov/pubmed/28315937
8. Mykletun A, Bjerkeset O, verland S, PrinceM, DeweyM, Stewart R. Levels of anxiety and depression
as predictors of mortality: the HUNT study. Br J Psychiatry [Internet]. 2009 Aug 2 [cited 2018 Jun 19];
195(02):118–25. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19648541
9. Sobocki P, Jönsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ
[Internet]. 2006 Jun [cited 2019 Sep 18]; 9(2):87–98. Available from: http://www.ncbi.nlm.nih.gov/
pubmed/17007486
10. Sobocki P, Lekander I, Borgström F, Ström O, RunesonB. The economic burden of depression in Swe-
den from 1997 to 2005. Eur Psychiatry [Internet]. 2007 Apr [cited 2018 Jun 19]; 22(3):146–52. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/17194573
11. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B. Depression, chronic diseases, and dec-
rements in health: results from theWorld Health Surveys. Lancet (London, England) [Internet]. 2007
Sep 8 [cited 2019 Sep 18]; 370(9590):851–8. Available from: https://linkinghub.elsevier.com/retrieve/
pii/S0140673607614159
12. Gili M, Garcia-Toro M, Vives M, Armengol S, Garcia-Campayo J, Soriano JB, et al. Medical comorbidity
in recurrent versus first-episode depressive patients. Acta Psychiatr Scand [Internet]. 2011Mar [cited
2019 Sep 18]; 123(3):220–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21118188
13. Kupfer DJ, Frank E, PhillipsML. Major depressive disorder: new clinical, neurobiological, and treatment
perspectives. Lancet (London, England) [Internet]. 2012Mar 17 [cited 2018 Jun 19]; 379(9820):1045–
55. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0140673611606028
14. RocaM, Armengol S, Garcı́a-Garcı́a M, Rodriguez-Bayón A, Ballesta I, SerranoMJ, et al. Clinical differ-
ences between first and recurrent episodes in depressive patients. Compr Psychiatry [Internet]. 2011
Jan [cited 2019 Sep 18]; 52(1):26–32. Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0010440X10000453PMID: 21220062
15. Frank E, Prien R, Jarrett R, Keller M, Kupfer D, Lavori P, et al. Conceptualization and rationale for con-
sensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.
Arch Gen Psychiatry. 1991; 48(9):851–5. https://doi.org/10.1001/archpsyc.1991.01810330075011
PMID: 1929776
16. Buckman JEJ, UnderwoodA, Clarke K, Saunders R, Hollon SD, Fearon P, et al. Risk factors for relapse
and recurrence of depression in adults and how they operate: A four-phase systematic review and
PLOS ONE Analysis of depressive episodes, their recurrence and pharmacologic treatment
PLOSONE | https://doi.org/10.1371/journal.pone.0233454 May 21, 2020 12 / 15
meta-synthesis. Clin Psychol Rev [Internet]. 2018 Aug [cited 2019Oct 6]; 64:13–38. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/30075313
17. Monroe SM, Harkness KL. Recurrence in Major Depression: A Conceptual Analysis. Psychol Rev.
2011;
18. Monroe SM, Harkness KL. Is depression a chronic mental illness? Psychol Med [Internet]. 2012May 14
[cited 2019 Sep 18]; 42(5):899–902. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21995936
19. EatonWW, Shao H, Nestadt G, Lee BH, BienvenuOJ, Zandi P, et al. Population-Based Study of First
Onset and Chronicity in Major Depressive Disorder. Arch Gen Psychiatry [Internet]. 2008May 1 [cited
2019 Sep 16]; 65(5):513. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18458203
20. SolomonDA, Keller MB, Leon AC, Mueller TI, Lavori PW, SheaMT, et al. Multiple recurrences of major
depressive disorder. Am J Psychiatry [Internet]. 2000 Feb 1 [cited 2019 Sep 16]; 157(2). Available from:
http://ajp.psychiatryonline.org/article.aspx?articleID=173950
21. SolomonDA. Multiple Recurrences of Major DepressiveDisorder. Am J Psychiatry. 2000 Feb; 157
(2):229–33. https://doi.org/10.1176/appi.ajp.157.2.229 PMID: 10671391
22. Hoertel N, BlancoC, OquendoMA,Wall MM, OlfsonM, Falissard B, et al. A comprehensivemodel of
predictors of persistence and recurrence in adults with major depression: Results from a national 3-year
prospective study. J Psychiatr Res [Internet]. 2017Dec [cited 2018 Jun 18]; 95:19–27. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/28759845
23. Steinert C, HofmannM, Kruse J, Leichsenring F. The prospective long-term course of adult depression
in general practice and the community. A systematic literature review. J Affect Disord [Internet]. 2014
Jan [cited 2019 Sep 18]; 152–154:65–75. Available from: https://linkinghub.elsevier.com/retrieve/pii/
S0165032713007465 PMID: 24210624
24. Spijker J, de Graaf R, ten HaveM, NolenWA, Speckens A. Predictors of suicidality in depressive spec-
trum disorders in the general population: results of the Netherlands Mental Health Survey and Incidence
Study. Soc Psychiatry Psychiatr Epidemiol [Internet]. 2010May 19 [cited 2019 Sep 18]; 45(5):513–21.
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19618093
25. Grieve SM, Korgaonkar MS, KoslowSH, Gordon E, Williams LM.Widespread reductions in gray matter
volume in depression. NeuroImageClin [Internet]. 2013 [cited 2019 Sep 18]; 3:332–9. Available from:
http://www.ncbi.nlm.nih.gov/pubmed/24273717
26. Dowlati Y, HerrmannN, Swardfager W, Liu H, Sham L, Reim EK, et al. A Meta-Analysis of Cytokines in
Major Depression. Biol Psychiatry [Internet]. 2010Mar 1 [cited 2019 Sep 18]; 67(5):446–57. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/20015486
27. Patten SB, Wang JL, Williams JV, Lavorato DH, Khaled SM, Bulloch AG. Predictors of the Longitudinal
Course of Major Depression in a CanadianPopulation Sample. Can J Psychiatry [Internet]. 2010Oct
[cited 2019 Sep 18]; 55(10):669–76. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20964946
28. LamRW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. CanadianNetwork
for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depres-
sive disorder in adults. J Affect Disord [Internet]. 2009Oct [cited 2019 Sep 18]; 117:S26–43. Available
from: http://www.ncbi.nlm.nih.gov/pubmed/19674794
29. Wang JL, Patten SB, Currie S, Sareen J, Schmitz N. Predictors of 1-year outcomes of major depressive
disorder among individualswith a lifetime diagnosis: a population-based study. Psychol Med [Internet].
2012 Feb 11 [cited 2019 Sep 18]; 42(2):327–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
21740627
30. Hirschfeld RM. Clinical importance of long-term antidepressant treatment. Br J Psychiatry Suppl [Inter-
net]. 2001 Sep [cited 2019 Sep 18]; 42:S4–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/
11532820
31. Gartlehner G, HansenR, Morgan L, Thaler K, Lux L, Van NoordM, et al. Comparative benefits and
harms of second-generation antidepressants for treatingmajor depressive disorder: an updatedmeta-
analysis. Ann Intern Med. 2011;6( 155 (11)):772–85. PMID: 22147715
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